Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2810741rdf:typepubmed:Citationlld:pubmed
pubmed-article:2810741lifeskim:mentionsumls-concept:C0030755lld:lifeskim
pubmed-article:2810741lifeskim:mentionsumls-concept:C0008972lld:lifeskim
pubmed-article:2810741lifeskim:mentionsumls-concept:C0108947lld:lifeskim
pubmed-article:2810741pubmed:issue8lld:pubmed
pubmed-article:2810741pubmed:dateCreated1989-12-6lld:pubmed
pubmed-article:2810741pubmed:abstractTextClinical evaluations of cefteram pivoxil (CFTM-PI, T-2588) were carried out. The obtained results are summarized as follows. 1. Clinical responses to CFTM-PI of 39 patients with pediatric infections were excellent in 16, good in 21, fair in 1 and poor in 1. The overall efficacy rate was 94.9%. 2. Bacteriologically, eradication rates for 39 isolates presumed to be pathogens were evaluated. The eradication rates obtained were 94.1% in 17 strains of Gram-positive cocci, 90.9% in 22 strains of Gram-negative rods. 3. Side effects observed were diarrhea in 2 patients, diarrhea and abdominal pain in 1, erythema and edema in 1. The incidence was 8.7%. An abnormal value found in clinical laboratory tests was eosinophilia in 1 patient. The results suggested that CFTM-PI might be a very useful and safe drug for the treatment of pediatric infections.lld:pubmed
pubmed-article:2810741pubmed:languagejpnlld:pubmed
pubmed-article:2810741pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2810741pubmed:citationSubsetIMlld:pubmed
pubmed-article:2810741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2810741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2810741pubmed:statusMEDLINElld:pubmed
pubmed-article:2810741pubmed:monthAuglld:pubmed
pubmed-article:2810741pubmed:issn0368-2781lld:pubmed
pubmed-article:2810741pubmed:authorpubmed-author:IshikawaKKlld:pubmed
pubmed-article:2810741pubmed:authorpubmed-author:SatohYYlld:pubmed
pubmed-article:2810741pubmed:authorpubmed-author:AkitaHHlld:pubmed
pubmed-article:2810741pubmed:authorpubmed-author:IwataSSlld:pubmed
pubmed-article:2810741pubmed:authorpubmed-author:SunakawaKKlld:pubmed
pubmed-article:2810741pubmed:issnTypePrintlld:pubmed
pubmed-article:2810741pubmed:volume42lld:pubmed
pubmed-article:2810741pubmed:ownerNLMlld:pubmed
pubmed-article:2810741pubmed:authorsCompleteYlld:pubmed
pubmed-article:2810741pubmed:pagination1780-90lld:pubmed
pubmed-article:2810741pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:meshHeadingpubmed-meshheading:2810741-...lld:pubmed
pubmed-article:2810741pubmed:year1989lld:pubmed
pubmed-article:2810741pubmed:articleTitle[A clinical study on cefteram pivoxil in pediatrics].lld:pubmed
pubmed-article:2810741pubmed:affiliationDepartment of Pediatrics, Ohta General Hospital.lld:pubmed
pubmed-article:2810741pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2810741pubmed:publicationTypeEnglish Abstractlld:pubmed